TY - JOUR
T1 - Correlation between imatinib pharmacokinetics and clinical response in japanese patients with chronic-phase chronic myeloid leukemia
AU - Takahashi, N.
AU - Wakita, H.
AU - Miura, M.
AU - Scott, S. A.
AU - Nishii, K.
AU - Masuko, M.
AU - Sakai, M.
AU - Maeda, Y.
AU - Ishige, K.
AU - Kashimura, M.
AU - Fujikawa, K.
AU - Fukazawa, M.
AU - Katayama, T.
AU - Monma, F.
AU - Narita, M.
AU - Urase, F.
AU - Furukawa, T.
AU - Miyazaki, Y.
AU - Katayama, N.
AU - Sawada, K.
PY - 2010/12
Y1 - 2010/12
N2 - Despite the outstanding results generally obtained with imatinib mesylate (IM) in the treatment of chronic myeloid leukemia (CML), some patients show a poor molecular response. To evaluate the relationship between steady-state trough plasma IM concentration (IM-Cmin) and clinical response in CML patients, we integrated data from six independent Japanese studies. Among 254 CML patients, the mean IM-Cmin was 1,010.5ng/ml. Importantly, IM-Cmin was significantly higher in patients who achieved a major molecular response (MMR) than in those who did not (P = 0.002). Multivariate analysis showed that an MMR was associated with both age (odds ratio (O=R) = 0.97 (0.958-0.995); P = 0.0153) and with IM-Cmin (OR = 1.0008 (1.0003-1.0015); P = 0.0044). Given that patients with IM-Cmin values 1,002ng/ml had a higher probability of achieving an MMR in our large cohort (P = 0.0120), the data suggest that monitoring of IM levels in plasma may improve the efficacy of IM therapy for CML patients.
AB - Despite the outstanding results generally obtained with imatinib mesylate (IM) in the treatment of chronic myeloid leukemia (CML), some patients show a poor molecular response. To evaluate the relationship between steady-state trough plasma IM concentration (IM-Cmin) and clinical response in CML patients, we integrated data from six independent Japanese studies. Among 254 CML patients, the mean IM-Cmin was 1,010.5ng/ml. Importantly, IM-Cmin was significantly higher in patients who achieved a major molecular response (MMR) than in those who did not (P = 0.002). Multivariate analysis showed that an MMR was associated with both age (odds ratio (O=R) = 0.97 (0.958-0.995); P = 0.0153) and with IM-Cmin (OR = 1.0008 (1.0003-1.0015); P = 0.0044). Given that patients with IM-Cmin values 1,002ng/ml had a higher probability of achieving an MMR in our large cohort (P = 0.0120), the data suggest that monitoring of IM levels in plasma may improve the efficacy of IM therapy for CML patients.
UR - http://www.scopus.com/inward/record.url?scp=78449312021&partnerID=8YFLogxK
U2 - 10.1038/clpt.2010.186
DO - 10.1038/clpt.2010.186
M3 - Article
C2 - 20980997
AN - SCOPUS:78449312021
SN - 0009-9236
VL - 88
SP - 809
EP - 813
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 6
ER -